C4 Therapeutics, Inc. Deferred Tax Assets, Operating Loss Carryforwards
C4 Therapeutics, Inc. (CCCC) had Deferred Tax Assets, Operating Loss Carryforwards of $100.15 million as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Operating Loss Carryforwards, Components
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-02-26
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $100.15M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $62.43M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $61.04M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $54.30M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $100.15M 10-K · filed 2026-02-26 |
| 2024-12-31 | $62.43M 10-K · filed 2026-02-26 |
| 2023-12-31 | $61.04M 10-K · filed 2025-02-27 |
| 2022-12-31 | $54.30M 10-K · filed 2024-02-22 |
| 2021-12-31 | $46.34M 10-K · filed 2023-02-23 |
| 2020-12-31 | $19.40M 10-K · filed 2022-02-24 |
| 2019-12-31 | $575.00K 10-K · filed 2021-03-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |